The mechanism explains why it lacks a benzodiazepine's downsides, and one finding closes a rare loop from measured deficit to biomarker. What is missing is replication from outside.
Selank has something almost nothing else on this site has: it is an approved prescription medicine. Russia licensed it in 2009 for generalised anxiety disorder, it sells there as a nasal spray, and it sits on the country's list of vital and essential drugs.
It also has a limitation that goes with that, and the two need holding together.
Nearly every published study on this compound comes from Russian institutions. Several of the key clinical papers appear in the same journal.
That is not an accusation of anything. The work is published, indexed and citable, and the mechanistic studies have appeared in international journals including Frontiers in Pharmacology and Behavioural Neurology.
But a compound whose whole clinical case sits inside one research tradition has not faced the thing that catches problems. That is independent replication, by people with no stake in the answer. A finding that survives a sceptical lab in another country is worth more than the same finding repeated at home. That test has not been run here.
Hold both halves. This is stronger human evidence than most compounds on this site can show. It is also narrower than the volume suggests.
Selank is seven amino acids long:
Thr-Lys-Pro-Arg-Pro-Gly-Pro
The first four are tuftsin, a fragment your own immunoglobulin G produces to support immune function. Researchers at the Institute of Molecular Genetics added Pro-Gly-Pro to the tail, which made the molecule stable enough to survive and reach the brain.
That heritage matters later, because it never stopped being an immune peptide.
The headline result is a 62-patient trial: 30 on Selank, 32 on medazepam, a benzodiazepine, in generalised anxiety disorder and neurasthenia.
Anxiety reduction came out similar in both groups. But the Selank group also showed effects the benzodiazepine did not: more energy and sharper thinking. And it avoided the sedation and mental dulling that came with the drug it was tested against.
Take that seriously, and take it carefully. A compound that matches a benzodiazepine on anxiety while sharpening thinking instead of dulling it would be a major finding. Which is exactly why it needs repeating outside the group that produced it. Big results carry a higher burden, not a lower one.
The interesting part is that there is a specific mechanistic reason it could work this way.
Benzodiazepines bind the GABA-A receptor directly and force the channel open harder. That is where the sedation, memory trouble, tolerance and withdrawal come from. You are overriding the system.
Selank does not bind that site. It acts as an allosteric modulator: it changes the receptor's shape so that GABA itself binds more effectively. It amplifies what your own inhibitory system is already doing rather than pushing past it.
Volkova and colleagues put evidence under this in 2016, tracking 84 neurotransmission genes in rat frontal cortex. Forty-five shifted within an hour and 22 at three hours. The pattern matched what direct GABA produced. Same system, different way in.
If that is right, the absence of tolerance and dependence is not luck. It follows from where the compound acts.
This one deserves its own space, because it is a proper closed loop and those are rare.
Your body makes enkephalins, natural calming peptides. Enzymes in the blood chew through them quickly, which limits how long they work.
Zozulya's group found that patients with generalised anxiety disorder have a shortened enkephalin half-life than healthy controls do. Their own calming peptides were being destroyed too fast. And enkephalin levels tracked how severe the symptoms were.
Selank inhibits those degrading enzymes — IC50 of 15 micromolar, more potent than bacitracin or puromycin, the standard laboratory inhibitors. And in the clinical trial, treatment raised the enkephalin measure back up.
So: a measured deficit, a mechanism that addresses it, and a biomarker that moves with the treatment. Very little in this field assembles all three pieces.
Here is the practical finding most people using this compound will not have accounted for.
Vasil'eva and colleagues compared intranasal against intraperitoneal administration in mice. The results were not the same drug at different doses.
Injected: GABA receptor binding in the frontal cortex up 38%, NMDA receptors unchanged.
Intranasal: NMDA receptor binding up 23%, GABA receptors unchanged.
Different receptor systems entirely, from the same peptide, depending on how it got in.
And every published clinical trial used the intranasal route. Anyone injecting this is not taking a more precise version of the tested compound. They are taking something whose brain chemistry, in the one study that compared the two, went somewhere else. That is the same problem the GHK-Cu evidence has, where the human trials were all topical and the popular route is injection.
The same study found the anxiolytic and nootropic effects appeared only in BALB/c mice — the anxiety-prone strain. In calm C57BL/6 mice, nothing.
That fits the modulation story. It corrects a deviation rather than pushing a normal system further. It also carries an unglamorous implication: if your baseline anxiety is not raised, the animal data suggests there may be nothing there for you to feel.
Neznamov's study of 20 patients found the response splits cleanly in two.
40% were rapid responders. Hamilton Anxiety scores fell from 20.3 to 7.0 by day three.
60% responded gradually, reaching clinically meaningful change around day 14.
The fast group could be told apart at baseline. More fatigue and more cognitive symptoms, plus clear EEG changes after a single dose: beta rhythm up, theta and slow alpha down.
A predictor of who responds fast, visible before treatment and confirmed by an objective measure after one dose, is unusual in this field. The practical version: if your anxiety runs with fatigue and mental fog, you may be in the fast group. And two weeks of nothing is not evidence it has failed.
The pharmacokinetics are worth stating because they look wrong at first.
Given intranasally, Selank appears in blood within 30 seconds and falls away within about five minutes. No metabolites turn up in urine — tissue peptidases dismantle it completely.
Yet the reported effects on gene expression, BDNF and neurotransmitter balance persist far longer, with anxiolytic benefit lasting roughly a week after the last dose.
That is not a contradiction. It is what you would expect from something that changes gene expression. The trigger passes in minutes; the response runs for days. It also shows that half-life predicts exposure, not how long an effect lasts — a point that cuts the other way for compounds whose schedules are built on a half-life figure.
Because it descends from tuftsin, this never stopped being an immune-active molecule.
Under social stress in animals it lowered three inflammatory signals — IL-1 beta, IL-6 and TNF-alpha — and brought the anti-inflammatory IL-4 back up. In people with anxiety-asthenic disorders, 14 days of treatment shifted Th1/Th2 balance and suppressed IL-6 gene expression in blood. A separate study found 34 inflammation-related genes altered in mouse spleen.
That fits an anti-stress compound, since chronic stress and chronic inflammation drive each other. It also means an active autoimmune condition is a reason for caution. That is easy to miss when you file the compound mentally as an anxiety drug rather than an immune one.
With a benzodiazepine. Medvedev's 2015 study found adding Selank to phenazepam reduced the benzodiazepine's side effects — attention and memory impairment, sedation, sexual disturbance, emotional flatness — both during treatment and after withdrawal. Interesting, and done under clinical supervision. Two compounds acting on the same system is not a combination to improvise with.
Human brain imaging. Panikratova, 2020, resting-state fMRI in 52 healthy participants: both Selank and Semax changed how strongly the right amygdala and the right temporal cortex talked to each other. That circuit handles emotion regulation. A human study, an objective measure, and a healthy population rather than a patient one.
Animal work. BDNF regulation in rat hippocampus. Protection against alcohol-related memory disturbance, again via BDNF. Enhanced diazepam effect under chronic mild stress — where, notably, Selank alone worked best in the absence of chronic stress.
Where it does not reach. The evidence base is generalised anxiety disorder and neurasthenia. Panic disorder and severe social anxiety are not what was studied, and reports there are correspondingly less consistent.
N-Acetyl Selank and N-Acetyl Selank Amidate cap one or both ends of the peptide to slow enzymatic breakdown.
Every published human trial used the original sequence. The changes are meant to extend stability rather than alter what the molecule does, but no clinical study has tested that assumption. Choosing a modified version means leaving behind the only reason to trust the compound in the first place.
The reported profile is unusually clean. Across the Russian trials: no sedation, no cognitive impairment, no tolerance, no withdrawal, no dependency, no acute toxicity at any dose studied. The main complaint is mild nasal irritation or an unpleasant taste at the back of the throat. Occasional headache, sometimes fatigue at higher doses, and a few reports of flatness or increased anxiety at high doses that resolve on reduction.
One clinical source notes nasal discolouration in around 10% and small blood glucose rises in around 7.4% of diabetic patients. Both figures need confirming; the diabetes one is worth knowing anyway.
And the observation worth ending on. The most common complaint about this compound is that it did not do much. That is a very different complaint from dependence and withdrawal, and it is a fair trade. But underwhelming is the failure mode to expect here, not a dramatic one.
Not studied in pregnancy. Active autoimmune conditions warrant care, for the tuftsin reason above.
The interaction that matters is psychiatric medication. Selank affects both GABA and serotonin systems, and no drug interaction studies have been published. Stacking it with an SSRI or SNRI is untested ground. Stacking it with a benzodiazepine, as the Medvedev study did, was done under medical supervision, and that is how it should stay. Alcohol and other depressants for the same reason.
One footnote that stands out on this site: it is not currently on the WADA prohibited list, unlike most compounds covered here.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
Research-grade material, sold for laboratory research use. We link to a single supplier rather than a list, so you know exactly where the recommendation goes. Check the certificate of analysis against what a COA can and cannot show before you buy anything.
Commercial link. Nothing on this page is a dose, a protocol, or a claim that this compound treats or prevents any condition.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
